Yang, L., Gao, Q., Gong, J., Hu, J., Shi, X., Peng, J., Wu, H., Wang, Y., Xu, H., Long, X., Yin, Q., Zhou, F. (2026). Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16172